Season 10, Episode 6 - Chris Miller, VP, Biometrics - Respiratory & Immunology & Stat. Innovation, AstraZeneca

·30 min·1 clip

I ended up in the best of both worlds as a career with biostatistics and data science in the healthcare field.

Bill Franks opens by framing Chris Miller's path from graduate school to senior leadership at AstraZeneca. Chris started in pharma R&D right after school and has spent almost his entire career with the company. Over his 30-plus years, he has held about ten roles, starting as principal statistician and rising to his current position. His climb stands out because he was one of the first non-PhD employees to break into senior clinical-side roles. The conversation begins with that career arc and uses it to show how analytics work evolves over time. Bill and Chris talk about the difference between the early discovery environment and the later development environment. In early drug discovery, the data volume is huge and the unknowns are substantial. Chris describes AI there as a way to find patterns, correlations, and possible targets rather than as something fully deployed in production. That makes the work more hypothesis generating than predictive in the classic operational sense. Once AI surfaces a pattern, teams can do more targeted testing to see whether it holds up. The discussion then shifts to the operational side of late-stage drug development. Chris describes a world built on handovers, locked datasets, analysis datasets, and formal reports. Those steps are still highly sequential and can take weeks or months. He explains that his team is now exploring agentic AI to take on pieces of those roles. The goal is to see whether AI agents can help with the repeated tasks involved in the process. Bill and Chris also touch on how AI is already being used inside large multinational companies for practical communication tasks. One example is drafting emails in a way that helps people communicate more clearly when English is not their first language. The tone stays grounded throughout. Chris does not present technology as magic. Instead, he treats it as a tool that fits differently depending on the level of uncertainty and the structure of the work. That perspective gives the episode a useful contrast between exploratory analytics and highly controlled operational analytics. The closing turns toward career advice and the limits of long-term planning. Chris reflects on how people can look back and make a career story seem inevitable. He argues that nobody really knows where they will be in five or ten years. The point is not to master the future. The point is to stay open to what the next step makes possible. That idea gives the episode a quiet finish and ties the technical discussion back to lived career experience.

As heard by us

A grounded pharma career story that ties early discovery pattern-finding to late-stage operational discipline.

Chris Miller's career story gives the episode its strongest shape, showing pharma analytics as a field that moves from early discovery, where AI can help surface patterns in huge, uncertain datasets, to late-stage development, where handoffs, reports, and rigid analysis steps…

Read the full review in PlayNext →

Why you'd press play

Hear how pharma data science moves from early discovery patterns to late-stage operational discipline.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Data Science Perspectives